MLSC Blood decontaminant recieves patent!!!

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks MLSC Blood decontaminant recieves patent!!!

Previous 10 Next 10

To: Cindy Powell who wrote (185)	3/16/2000 10:35:00 AM
From: P.S.N.	of 196

Cindy, thanks for the INFO looks good. :-) PSN

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: P.S.N. who wrote (186)	3/16/2000 3:57:00 PM
From: Cindy Powell	of 196

So are you going for the gusto with MLSC, P.S.N.? I have always believed in this company and have held even during their darker hours. Shooting pennies has a good reputation from what I understand. Hope you were able to pick up some shares before this run! Wow is all I can say. Goooooooooooo MLSC!!! Best, Cindy

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (187)	3/28/2000 11:31:00 AM
From: Cindy Powell	of 196

Still holding MLSC guys and gals. Maybe a mistake and in retrospect I should-a sold on the run, but I didn't suspect such a royal pump and dump. The shooting pennies exposure was good for investor awareness, but I don't like the way it was played as a pumper dumper. News should be forthcoming, but is taking longer than I expected. Maybe a good accumulation level here, but MLSC should still be considered risky and for speculative players only. Best of luck, Cindy

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (188)	11/29/2000 1:06:50 PM
From: Cindy Powell	of 196

Howdy folks, MLSC Receives $500,000 in Funding. I'm still holding my shares, and am still hoping that they get things going. More news and activity is much needed for us longs. MLSC states that funding is achieved because there is a fundamental belief in the possibility for MDI-P, and while I share that belief, I think they better improve shareholder relations and launch a more effective investor relations campaign. People are left in the dark too much with this company and are losing faith and patience. Monday November 20, 4:45 pm Eastern Time Press Release SOURCE: Medical Discoveries, Inc. MDI Receives Funding to Continue Studies of MDI-P; Medical Discoveries, Inc. Signs Agreement with Peregrine Properties, LLC SALT LAKE CITY, Nov. 20 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) announced today that Peregrine Properties, LLC has agreed to provide $500,000 to fund critical testing and research steps necessary to continue development of MDI's primary product, an anti-viral (HIV/AIDS), anti-bacterial and anti-fungal drug named MDI-P. Under terms of the agreement, MDI will continue to study the toxicology and chemistry of the drug and conduct laboratory and clinical studies of the drug's efficacy. The research activities will be directed by Dr. William J. Novick, MDI's Vice President and Chief Technical Officer. Upon completion of the studies, Peregrine Properties, LLC will receive 5.5 million shares of common stock and representation on MDI's Board of Directors in exchange for ownership of the studies and results. Peregrine Properties is a Utah limited liability company organized in March, 1996. Peregrine Properties is a development company owned by J. Douglass Bowers and Carl R. Faulkner. The primary business activity of the company has been real estate development. According to Carl Faulkner, ``the investment in the research for MDI's continued development of MDI-P was made to facilitate the completion of the studies, unencumbered by any other pressures. We believe in the future of MDI and their products. We are convinced that the research studies will demonstrate the potential good of MDI-P for the world.'' Formed in 1991, Medical Discoveries, Inc. is a development-stage biopharmaceutical research company engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. Information in this press release relating to the potential of MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to the Company's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect the Company's business is set forth in the Company's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission. SOURCE: Medical Discoveries, Inc. Email this story - Most-emailed articles - Most-viewed articles -------------------------------------------------------------------------------- More Quotes and News: Medical Discoveries Inc (OTC BB:MLSC.OB - news) Related News Categories: biotech, medical/pharmaceutical --------------------------------------------------------------------------------

Share	RecommendKeepReply Mark as Last Read

To: Cindy Powell who started this subject	1/12/2001 12:05:24 PM
From: Eye	of 196

It's been quite an educational experience watching this the past couple years, and needless to say I am really glad that I didn't go long on this stock. It's still fun to watch though. Hope it does well for all who hold, but I think I'll continue to shun penny stocks.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Eye who wrote (190)	1/17/2001 1:00:48 PM
From: Cindy Powell	of 196

You are wise to shun the pennies and just be a watcher. MLSC has been one of my more disappointing holdings, and I wish I was just a watcher rather than a shareholder. I'm done with pennies even with play money. I could have had more fun playing the slots! There are too many good nasdaq companies that aren't fraught with the challenges and uphill battles that pennies have. Not to say that alot of nasdaq companies aren't junk, as evidenced by last years dot com collapse, but pennies are just too risky in my opinion. Here are a couple of new press releases that shows that MLSC is still working towards their goals. Hopefully, this stock will bounce back. Take care, Cindy

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (191)	1/17/2001 1:03:44 PM
From: Cindy Powell	of 196

Study Validates Microbicidal Effectiveness of Medical Discoveries, Inc. Novel Drug, 'MDI-P' Peer-Reviewed Research Paper Details Sterilization Effectiveness SALT LAKE CITY, Jan. 10 /PRNewswire/ -- A new study on the microbe-killing properties of MDI-P, using four microorganisms that are difficult to eradicate in the hospital environment, has been completed at the Infectious Diseases Section of the Stratton VA Medical Center in Albany, New York. The infectious diseases research group, headed by Aldona Baltch, M.D., found that MDI-P is a highly effective microbicide for the organisms studied. The microbicidal effect of MDI-P is very rapid and it retains high microbicidal activity even in the presence of 50% human blood serum. There are no obvious adverse effects on the tissues of mice injected intravenously with MDI-P and preliminary results suggest that the microbicidal activity of MDI-P is relatively stable. The results of this study suggest that MDI-P may be useful for disinfection of inanimate surfaces, cold sterilization of medical devices, antisepsis, and irrigation therapy for wounds and ulcers. The findings of Dr. Baltch's group have been published in ``The American Journal Of Infection Control'' (AJIC 2000;28:251-7), the official journal of the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC). ``AJIC'' covers key topics and issues in the field of infection control, with peer-reviewed articles ranging from practical, clinically applicable topics to original, cutting-edge scientific research. ``AJIC'' is a highly respected resource on infection control, epidemiology, quality assurance, occupational health, and disease prevention and is widely read by infection control professionals, including physicians, nurses, and epidemiologists. In addition to the ``AJIC'' paper, Dr. Baltch's work on MDI-P has been published in the abstracts of, and presented at, the 97th and 98th Annual Meetings of The American Society of Microbiology. The research was supported by Medical Discoveries, Inc. and, in part, by the Research Service of the Veterans Administration. The four microorganisms used in the studies were Pseudomonas aeruginosa, Staphylococcus aureus, and Legionella pneumophila, all bacteria, and Candida albicans, a yeast (a type of fungus). These organisms were studied because each is an important human pathogen, is commonly found in the hospital environment, and presents difficulties with regard to eradication in that environment. The microbicidal activity of MDI-P against these organisms was tested at several concentrations and in the presence and absence of human blood serum. In addition, the effects of MDI-P on the morphology of the microbial cells were studied by Gram staining and transmission electron microscopy. Morbidity, mortality, and tissue toxicity were also studied using laboratory mice. In addition to its microbicidal properties, MDI-P was found to be inexpensive, simple to prepare, apparently harmless to inanimate surfaces, and without significant odor. It retained its microbicidal activity over a pH range from approximately 6.5 to 9. Dr. Baltch's paper also cited other published research regarding the microbicidal activity of MDI-P against bacteria, yeast, and viruses. She called for further testing in order to establish the most useful applications and the exact chemical composition of MDI-P. MDI-P is a proprietary new (novel) preparation produced by Medical Discoveries, Inc. (MDI) and protected directly or indirectly by eight original U.S. patents, covering both the production and application of the product. Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. MDI is currently attempting to secure capital commitments to finance continued research and testing of its novel drugs and technologies. Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission. SOURCE: Medical Discoveries, Inc. Wednesday January 10, 10:36 am Eastern Time Press Release SOURCE: Medical Discoveries, Inc.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (192)	1/17/2001 1:04:57 PM
From: Cindy Powell	of 196

Medical Discoveries, Inc. Receives Eighth Patent SALT LAKE CITY, Jan. 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC: MLSC - news) has received Patent Number 6,117,285 from the United States Patent And Trademark Office, entitled ``System For Carrying Out Sterilization Of Equipment.'' Medical Discoveries, Inc. (MDI) now has a total of eight granted patents relating to the company's proprietary electrolysis devices, methods and the patented products and applications derived therein. The family of patents represents the continued development of MDI's technology and intellectual property, begun in 1992 with proprietary hydrolysis of saline solutions for microbicidal applications and the development of a patented machine to produce these products. MDI's patents and resulting intellectual properties now span more than a decade of research and development, and include: Patent No. Patent No. Patent No. Patent No. 5,334,383 5,507,932 5,560,816 5,622,848 "Electrically "Apparatus For "Method For "Electrically Hydrolyzed Electrolyzing Electrolyzing Hydrolyzed Saline Salines As Fluids" Fluids" Solutions As In Vivo [1996] [1996] Microbicides Microbicides For In Vitro For Treatment Of Treatment Of Cardiomyopathy Contaminated And Multiple Fluids Containing Sclerosis." Blood" [1994] [1997] Patent No. Patent No. Patent No. Patent No. 5,674,537 5,731,008 6,007,686 6,117,285 "An Electrolyzed "Electrically "System For "System For Saline Solution Hydrolyzed Electrolyzing Carrying Out Containing Salines As Fluids For Use Sterilization Concentrated Microbicides" As Antimicrobial Of Equipment" Amounts Of Ozone [1998] Agents" [2000] And Chlorine [1999] Species" [1997] The Company has foreign PCT patent applications pending, corresponding to the above-granted United States patents. Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi. In 1994, the Company received its first patent relating to a drug based upon its proprietary electrolysis technology. This drug bears the code name MDI-P. MDI-P is a solution-based drug, which is produced by the electrolysis of saline, using a patented instrument with proprietary electrodes. This solution has a significant oxidation reduction potential due to a mixture of oxidative products resulting from electrolysis. Medical Discoveries, Inc. has identified several major target markets for its innovative new drug MDI-P. Each contains opportunities for MDI-P to play a major role in existing and new treatments of major diseases, as well as sterilization and disinfectant applications that represent major advances over current technologies. Medical Discoveries, Inc. intends to move forward in these areas of continued testing and development in the near term, while continuing to research and investigate additional applications for the Company's proprietary technology. MDI intends to vigorously pursue additional patents for its applications while safeguarding the Company's current intellectual properties. Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. MDI is currently attempting to secure capital commitments to finance continued research and testing of its novel drugs and technologies. Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission. SOURCE: Medical Discoveries, Inc. Wednesday January 10, 10:40 am Eastern Time Press Release SOURCE: Medical Discoveries, Inc.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (193)	3/31/2001 12:11:54 AM
From: Cindy Powell	of 196

Ninth MDI Patent Expands Security of Basic Technology SALT LAKE CITY, March 28 /PRNewswire/ -- Medical Discoveries, Inc. (OTC: MLSC - news) has been notified that Japanese Patent Application Number 508856/96 entitled ``System And Method For Carrying Out Sterilization'' will issue in the near future. The new patent claims priority to U.S. Patent No. 5,507,932, ``Apparatus For Electrolyzing Fluids,'' issued to Medical Discoveries, Inc. in 1996. This patent was the second in a family of additional patents in the U.S. and elsewhere that defines and safeguards the proprietary electrolysis technology used by MDI. Once this patent issues, Medical Discoveries, Inc. (MDI) will have a total of nine granted patents relating to the company's proprietary electrolysis devices, methods, and the patented products and application derived therein. The family of patents represents the continued development of MDI's technology and intellectual property, which began in 1992 with proprietary hydrolysis of saline solution for microbicidal applications and the development of a patented machine to produce these products. Newly allowed Japanese Patent Application Number 508856/96, once issued, will cover similar subject matter in Japan as that claimed in U. S. Patent 5,507,932. Specifically, an apparatus for electrolyzing fluids for in vivo treatment of physiological fluids for the destruction of microbes in warm-blooded animals is claimed. The apparatus can be used with a variety of fluids including whole blood, plasma and cell-containing fluids, without introducing harmful substances into the electrolyzed fluids. MDI's patents and resulting intellectual properties now span more than a decade of research and development. Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi. In 1994, the Company received its first patent relating to a drug based upon its proprietary electrolysis technology. This drug bears the code name MDI-P. Formed in 1991, Medical Discoveries, Inc. is a public traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statement because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission. SOURCE: Medical Discoveries, Inc.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (194)	6/29/2001 2:28:51 AM
From: Eye	of 196

Wow, what happened to this company? Stopped watching it a few months ago ... now I see they haven't really gotten anywhere. Not too many people are with the company either and I notice their bigname executive has seemed to have left. Still, it's educational to watch these speculative stocks. I'll go try and catch up on the recent news of MLSC to find out what happened.

Share	RecommendKeepReply Mark as Last Read